Form 6-K Transition Therapeutics For: Nov 10

�

�

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

�

FORM 6-K

�

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

�

For the Month of November 2014

�

Commission File No.: 001-33514

�

TRANSITION THERAPEUTICS INC.

�

101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7

(Address of Principal Executive Office)

�

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F  Form 40-F 

�

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes  No 

�

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes  No 

�

A copy of the Registrant’s report of voting results for its annual general meeting of shareholders held on December 13, 2013 is furnished herewith and is incorporated by reference into the following Registration Statements:

�

Registration Statement on Form S-8 No. 333-157279
Registration Statement on Form F-3 No. 333-189879

�

�

�

EXHIBITS

�

The following information is furnished to the SEC as part of this report on Form 6-K:

�

Exhibit No.	Document
�	�
99.1	Press Release dated November 10, 2014 - Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2015 Financial Results on Wednesday, November 12th, at 4:30 P.M. EST

�

�

SIGNATURES

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

�

�	�	TRANSITION THERAPEUTICS INC.		�
�	�	�	�	�
Date:	November 10, 2014	By:	/s/ Nicole Rusaw	�
�	�	Name:	Nicole Rusaw	�
�	�	Title:��	Chief Financial Officer	�

�

�

Exhibit 99.1

�

Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2015 Financial Results on Wednesday, November 12th, at 4:30 P.M. EST

TORONTO, Nov. 10, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, November 12th, 2014 at 4:30 P.M. EST to discuss First Quarter Fiscal 2015 financial results. ��Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. �Transition will announce its financial results for this period in a press release to be issued prior to the call.� In order to participate in the conference call, please call (800) 909-7810 (North America), (416) 981-9010 (International).� �A replay of the conference call will be available on Transition's website www.transitiontherapeutics.com for seven days following the call.

About Transition

Transition is a biopharmaceutical development company, advancing novel therapeutics for CNS and metabolic disease indications. The Company's wholly-owned subsidiary, Transition Therapeutics Ireland Limited is developing CNS drug candidate ELND005 for the treatment of Alzheimer's disease and Down syndrome.� Transition's lead metabolic drug candidate is TT401 (LY2944876) for the treatment of type 2 diabetes and accompanying obesity. The Company's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials and potential efficacy of its products. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.

�

%CIK: 0001399250

For further information: on Transition, visit www.transitiontherapeutics.com or contact: Dr. Tony Cruz, Chief Executive Officer, Transition Therapeutics Inc., Phone: 416-260-7770, x.223, [email protected]

CO: Transition Therapeutics Inc.

CNW 06:01e 10-NOV-14

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• KP Tissue Declares a Quarterly Dividend of $0.21 per Common Share
• DAVIDsTEA Opens Flagship Store at Square One Shopping Center in Mississauga
• Plurilock to Host Investor Webinar on Its Expanding U.S., Canadian, and NATO Contracting Portfolio